ANVS homework Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
set stop lose 12.50
entry $13
exit $16
−6.22USD
−56.20 MUSD
8.14 M
About Annovis Bio, Inc.
Sector
CEO
Maria-Luisa Maccecchini
Headquarters
Malvern
Website
Employees (FY)
6
Founded
2008
FIGI
BBG00PN9XD40
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ANVS is 11.88 USD — it has increased by 3.39% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Annovis Bio, Inc. stocks are traded under the ticker ANVS.
Annovis Bio, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
ANVS stock is 8.25% volatile and has beta coefficient of 0.86. Check out the list of the most volatile stocks — is Annovis Bio, Inc. there?
ANVS earnings for the last quarter are −1.63 USD per share, whereas the estimation was −1.09 USD resulting in a −49.54% surprise. The estimated earnings for the next quarter are −1.78 USD per share. See more details about Annovis Bio, Inc. earnings.
Yes, you can track Annovis Bio, Inc. financials in yearly and quarterly reports right on TradingView.
ANVS stock has risen by 8.00% compared to the previous week, the month change is a 0.59% rise, over the last year Annovis Bio, Inc. has showed a 24.19% decrease.
ANVS net income for the last quarter is −22.21 M USD, while the quarter before that showed −14.72 M USD of net income which accounts for −50.94% change. Track more Annovis Bio, Inc. financial stats to get the full picture.
Today Annovis Bio, Inc. has the market capitalization of 130.81 M, it has increased by 13.99% over the last week.
No, ANVS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ANVS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Annovis Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 24, 2024, the company has 6.00 employees. See our rating of the largest employees — is Annovis Bio, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Annovis Bio, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Annovis Bio, Inc. stock shows the sell signal. See more of Annovis Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Annovis Bio, Inc. future price: according to them, ANVS price has a max estimate of 72.00 USD and a min estimate of 13.00 USD. Read a more detailed Annovis Bio, Inc. forecast: see what analysts think of Annovis Bio, Inc. and suggest that you do with its stocks.